| Chronic Hepatitis B | |
|---|---|
| Opening Lecture 1: Acute Hepatitis in the era of Covid 19 Prof. Seng Gee Lim View Bio |
|
| Opening Lecture 2: Prospects For Functional Cure Prof. Patrick Marcellin View Bio |
|
| CHB Therapy part 1 | |
| Patient selection for HBV therapy: lessons from REVEAL Prof. Teerha Piratvisuth View Bio |
|
| Biomarkers for HBV management Prof. Man Fung Yuen View Bio |
|
| The good and bad of HBV flares Dr. James Fung View Bio |
|
| Case Study 1: A case of chronic hepatitis B flare Dr. Tan Youg Chuan |
|
| CHB Treatment part 2 | |
| Stopping NUCs and guidelines Prof. Pietro Lampertico View Bio |
|
| New findings of NUCs: Implication for HCC prevention Prof. Man Fung Yuen View Bio |
|
| Is there still a role for interferon in CHB? Prof. Teerha Piratvisuth View Bio |
|
| Case Study 2: A case of antiviral therapy for chronic hepatitis B Dr. Tan Yong Chuan |
|
| HBV & HDV co-infection | |
| Epidemiology and risk of liver disease with HDV Prof. Pei Jer Chen View Bio |
|
| Advances in therapy for HDV Prof. Pietro Lampertico View Bio |
|
| Q & A |
SHC 2022 Online Conference Scientific Programme
Click on "WATCH VIDEO" in the Scientific Programme below to watch the Expert’s video on the topic presented.
May, 2022
30
May, 2022
31
| Advanced Liver Disease and NASH/NAFLD | |
|---|---|
| Advanced Liver Disease Symposium | |
| Terlepressin for Hepatorenal Syndrome Prof. Arun Sanyal View Bio |
|
| Debate: Should albumin replacement be used in cirrhosis: Yes : Prof. Guadalupe Garcia Tsao View Bio No: Prof. Rajender Reddy View Bio |
|
| Organ Support for Liver Failure Prof. Rajender Reddy View Bio |
|
| Baveno VII: prevention of first onset decompensation Prof. Guadalupe Garcia Tsao View Bio |
|
| Differential risk of HCC in aetiology and stage of cirrhosis Prof. Hashem el-Serag View Bio |
|
| Case Study 1: Advanced Liver Disease Dr. Tang Si Ying |
|
| Non-Alcoholic Fatty Liver Disease Symposium | |
| Non-invasive biomarkers for NASH Prof. Rohit Loomba View Bio |
|
| NASH is not Just about the Liver Dr. Mark Muthiah View Bio |
|
| Role of Diabetic drugs in NASH Prof. Arun Sanyal View Bio |
|
| Bariatric intervention for NASH Dr. Asim Shabbir View Bio |
|
| Cutting Edge therapeutics in NASH Prof. Arun Sanyal View Bio |
|
| Debate: Antifibrotics for NASH – is the door closed? Yes: Prof. Vincent Wong View Bio No: Prof. Rohit Loomba View Bio |
|
| Case Study 2: NASH Dr. Margaret Teng |
June, 2022
1
| Liver Transplantation and Hot Topics in Hepatology | |
|---|---|
| Liver Transplantation | |
| Changes in liver transplantation waiting list in the West Prof. Rajender Reddy View Bio |
|
| ACLF and liver transplant: predictors of success Dr. James Fung View Bio |
|
| Hepato-Pulmonary complications requiring liver transplant Dr. Mark Muthiah View Bio |
|
| Debate: Immunotherapy versus Liver Transplant for HCC FOR Immunotherapy: Dr. Chee Cheng Ean View Bio Vs FOR Liver Transplant: Prof. Glenn Bonney View Bio |
|
| Downstaging for LTx in the era of immunotherapy Prof. Rajender Reddy View Bio |
|
| Case Study 1: Liver Transplantation Dr. Benjamin Tay |
|
| Hot Topics In Hepatology Symposium | |
| Non-invasive diagnosis of liver fibrosis: physical, biological or both? Professor Vincent Wong View Bio |
|
| Autoimmune and Cholesteric Liver Disease update Prof. Jia Jidong View Bio |
|
| Microbiome therapy for liver disease: fantasy or reality? Dr. Jonathan Lee View Bio |
|
| Stem cell therapy for liver disease: update 2022 Prof. Yock Yong Dan View Bio |
|
| Case Study 2: Hot Topics in Hepatology Dr. James Ho |
June, 2022
2
| HCC Symposium | |
|---|---|
| HCC Symposium Part 1 | |
| Updates in NAFLD-related HCC: Epidemiology, who and how to screen? Dr. Daniel Huang View Bio |
|
| Biomarkers of HCC: is GALAD ready for primetime? Prof. Hashem el-Serag View Bio |
|
| Debate: Can locoregional therapy replace surgery for small HCC Yes: Dr. Kamarjit Singh Mangat View Bio Vs No: Dr. Alfred Kow View Bio |
|
| Neo Adjuvant therapy for small HCC: success or failure? Dr. Raghav Sundar View Bio |
|
| HelioLiver – A Multi-Analyte Blood Test for Accurate and Early Detection of Hepatocellular Carcinoma Dr. William Pirjamali View Bio |
|
| HCC Symposium Part 2 | |
| Debate: Intermediate HCC should be managed with systemic therapy Yes : Prof. Ann-Lii Cheng View Bio Vs No : Prof. Pierce Chow View Bio |
|
| Immunotherapy for HCC: which combinations to use? Prof. Ann-Lii Cheng View Bio |
|
| Rescue therapy for immunotherapy failure Prof. Toh Han Chong View Bio |
|
| Case Study: HCC Dr. Tang Si Ying |